Active Ingredient History

  • Now
Centanafadine (INN) is a serotonin-norepinephrine-dopamine reuptake inhibitor (SNDRI) that began its development with Euthymics Bioscience after they acquired DOV Pharmaceutical. It was developed as a treatment for attention-deficit hyperactivity disorder (ADHD) and inhibits the reuptake of norepinephrine, dopamine, and serotonin with a ratio of 1:6:14, respectively. In 2011, Euthymics Bioscience spun off its development of centanafadine to a new company called Neurovance. In March 2017, Otsuka Pharmaceutical acquired Neurovance and the rights to centanafadine. As of January 2018, Otsuka's pipeline indicates it is in Phase III clinical trials.   Wikipedia

  • SMILES: C1NC[C@@]2(C[C@H]12)c3ccc4ccccc4c3
  • Mol. Mass: 209.29
  • ALogP: 2.7
  • ChEMBL Molecule:
More Chemistry
1-(naphthalen-2-yl)-3-azabicyclo(3.1.0)hexane | centanafadine | eb-1020


Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue